Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with mitomycin or raltitrexed for colorectal cancer spread to the peritoneum

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective Phase I, dose-escalation trial testing pressurized intraperitoneal aerosol chemotherapy (PIPAC) given with either mitomycin or raltitrexed in patients with colorectal adenocarcinoma limited to peritoneal metastasis. Patients receive repeated laparoscopic PIPAC procedures with escalating drug doses (mitomycin 5–20 mg/m2; raltitrexed 1–3 mg/m2) combined with standard systemic first-line chemotherapy. The primary goal is to determine the maximum tolerated dose (MTD) and to characterize safety and tolerability when PIPAC is combined with systemic treatment. Secondary observations include feasibility, procedural complications, and early signals of tumor response or symptom benefit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with peritoneal metastatic adenocarcinoma of colorectal origin, confirmed by histopathology, and without metastasis to other sites.
2. No gender limitation, aged 18 to 75 years old;
3. ECOG score ≤2;
4. Subjects without other malignant diseases;
5. Subjects without laparoscopic surgery contraindications;
6. Expected survival period \> 6 months;
7. Able to comprehend and sign the informed consent form;
8. The function of important organs should meet the following requirements; The absolute neutrophil count (ANC) is ≥1.5×10\^9/L; Platelets ≥ 100×10\^9/L; Hemoglobin ≥8.0g/dl (Note: It is acceptable to achieve hemoglobin ≥8.0g/dl through blood transfusion or other interventions); serum albumin ≥2.8g/dL; Bilirubin ≤1.5 times ULN, ALT and AST ≤1.5 times ULN; if there is liver metastasis, ALT and AST ≤5 times ULN; Creatinine clearance rate ≥50mL/min

Exclusion Criteria:

1. Subjects with gastrointestinal obstruction;
2. Subjects who rely entirely on parenteral nutrition;
3. Subjects with decompensated ascites;
4. Subjects with severe abdominal infection (peritonitis);
5. Subjects with extensive abdominal adhesion;
6. Subjects who underwent both tumor reduction surgery and gastrointestinal resection and reconstruction simultaneously;
7. Subjects with portal vein thrombosis;
8. Patients with severe or uncontrolled medical conditions and infections (including atrial fibrillation, angina pectoris, heart failure, ejection fraction less than 50%, refractory hypertension, etc.);
9. Previously allergic to chemotherapy drugs;
10. Individuals with severe heart and lung, liver and kidney, blood system, or mental illnesses, as well as those who abuse drugs;
11. Pregnant or lactating women;
12. Patients who have participated in or are currently participating in other clinical trials within 3 months;
13. Other situations where the researchers believe that the patient is not suitable to participate in this trial;
14. Previously had a history of neurological or psychiatric disorders that would affect study informed consent or follow-up evaluation, such as severe depression or dementia;

Where it's running

• Second Affiliated Hospital, Zhejiang University School of Medicine 88 Jiefang Road Hangzhou, Zhejiang 310009, China
  Hangzhou, Other (Non U.s.), China Recruiting

Study contacts

• Study coordinator: Lifeng Sun
• Email: sunlifeng@zju.edu.cn
• Phone: 86-(571)-8778-3586

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• HDM2017 combination therapy in advanced colorectal cancer

  A small and mid-size study tests HDM2017 with standard chemotherapy and targeted drugs to see if it’s safe and may help people with unresectable or metastatic colorectal cancer.

  Recruiting Phase 1/2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07805551

• Radical Surgery vs Non-Surgery in Gastric Cancer with Peritoneal Metastasis after Successful Conversion Therapy

  This study checks whether removing the stomach and nearby lymph nodes helps people with gastric cancer that has spread to the peritoneum after successful conversion therapy.

  Recruiting Phase 3 Shanghai Cancer Hospital, China · Beijing, Beijing Municipality and 30 other locations · NCT07789184

• Retlirafusp alfa with bevacizumab and chemotherapy (with or without short radiotherapy) for colorectal cancer liver metastases

  This study tests whether adding retlirafusp alfa to bevacizumab and chemotherapy, with or without short-course radiotherapy, can help patients with advanced colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07728019

• SHR-1701 with short-course radiotherapy and CAPOX before surgery for locally advanced rectal cancer

  This will test whether adding the drug SHR-1701 to short-course radiotherapy plus CAPOX before surgery helps people with locally advanced rectal cancer.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07478731

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.